

NOV 28 1989

THE

# CANCER LETTER

P.O. Box 15189 WASHINGTON, D.C. 20003 TELEPHONE 202-543-7665

Vol. 15 No. 45  
Nov. 24, 1989

© Copyright 1989 Cancer Letter Inc.  
Price \$185 Per Year North America  
\$200 Per Year Elsewhere

## Review Guidelines For Comprehensive Centers Drafted, NCAB To Consider At December Meeting

A draft of review guidelines for the designation of cancer centers as comprehensive have been sent to cancer center directors and members of the National Cancer Advisory Board for their comment.

(Continued to page 2)

### In Brief

## McDonnell Foundation Selects Five For Awards; James Benson Is Named Interim FDA Head

FIVE PHYSICIANS were selected from major research centers last week by the James S. McDonnell Foundation as recipients of career development awards in molecular medicine and oncology. Each will receive \$125,000 a year for three years and the sponsoring institution will receive an additional 10 percent for a total three year award of \$412,500. The awards are dedicated to attracting new investigators to cancer research. Winners were **Paul Rothman**, Columbia Univ. Comprehensive Cancer Center; **Mark Siegelman**, Stanford Univ. School of Medicine; **Stephen Tapscott**, Univ. of Washington/Fred Hutchinson Cancer Center; **Emmett Schmidt**, Harvard Univ./Massachusetts General Hospital Cancer Center; and **Paul Celano**, Johns Hopkins School of Medicine. . . **JAMES BENSON**, acting deputy commissioner of FDA for the last 18 months, has been named interim commissioner until a search committee finds a replacement for Frank Young, who resigned last week. The search is expected to take at least six months. . . **NEW MEMBERS** of NCI's Div. of Cancer Etiology Board of Scientific Counselors are **Webster Cavenee**, director of the Ludwig Institute for Cancer Research; **Stephen Hecht**, director of research for the American Health Foundation; and **Marcel Baluda**, professor of pathology at Univ. of California (Los Angeles). Cavenee and Hecht have previously served on the board. . . **CARLO CROSE**, director of Fels Institute for Cancer Research and Molecular Biology, has been appointed editor in chief of "Cancer Research" by the American Assn. for Cancer Research board of directors. He will start a five year term in January, replacing Peter Magee, who has been editor since 1980. . . **ERKKI RUOSLAHTI**, president and chief executive officer of the La Jolla Cancer Research Foundation, was appointed editor in chief of "Cell Regulation," a new journal published by the American Society for Cell Biology. Monthly publication is scheduled to begin in January. . . **MINORITY BIOMEDICAL** Research Support Program, formerly operated out of the NIH Div. of Research Resources, now is administered by the National Institute of General Medical Sciences.

1.7% Cut Expected  
In NCI Budget Under  
Deficit Agreement  
... Page 4

Strict Regulation  
Of Tobacco Products  
Proposed In Senate  
... Page 4

Oncology Nursing Exam  
To Be Offered In 1990;  
79% Passed Last Year  
... Page 5

NCI Advisory Group,  
Other Cancer Meetings  
For Dec., Jan., Future  
... Page 6

New Publications  
... Page 7

RFPs Available  
... Page 8

## Review Guidelines For Comprehensive Centers Drafted, NCI Seeks Comment

(Continued from page 1)

The draft guidelines instruct reviewers to approve a center for comprehensive recognition only if it meets all eight of the criteria for comprehensiveness (published last week in *The Cancer Letter*.)

NCI is still soliciting comments on the review guidelines, and they will be discussed at the NCAB's next meeting in December. Following are excerpts of the review guidelines and application procedures:

**Procedures for applying:** As with new or competing Cancer Center Support Grants, it is strongly encouraged as a preliminary step in preparing both new and competing Requests for Comprehensive Designation that the applicant call the Cancer Centers Branch for assistance regarding the nature and content of the application. Applicants are asked to begin the dialogue with NCI staff at least six months prior to the planned submission of a new Cancer Centers Support Grant. Applicants should contact: Chief, Cancer Centers Branch, Div. of Cancer Biology & Diagnosis, NCI, Executive Plaza North Rm 308, 6130 Executive Blvd., Bethesda, MD 20892, phone 301/496-8531.

Applicants will submit a Request for Comprehensive Designation at the time of submission of their new or renewal Cancer Center Support Grant application. For each of the eight programmatic elements (the eight criteria), the applicant must document the ways in which the center's programs fulfill the criteria for that element. Since the submitted Cancer Center Support Grant application is a companion document for this review process, the details of specific center programs need not be repeated in this Request although a concise summary of how the center programs interact to address the specific criteria for

comprehensiveness is particularly important.

**Requests for interim designation:** During a two-year period beginning Jan. 1, cancer centers with active support grants, including current comprehensive cancer centers, may apply directly to NCI for administrative review of their eligibility to utilize or retain, on an interim basis, the designation, "NCI-Designated Comprehensive Cancer Center."

**Review Procedures:** The decision for comprehensiveness designation will be based in all cases on recommendations resulting from a review process that provides a measure of separation between the review of the support grant and the companion request for comprehensiveness. The separation is intended to minimize the impact of the comprehensiveness review on the review of the existing support grant or pending application for a support grant. Further, the process employed conserves to the maximum extent the traditional NIH dual review system involving the initial review by a chartered review committee, the Cancer Center Support Grant Review Committee (CCS), followed by a final review by the National Cancer Advisory Board.

The initial review of the Cancer Center Support Grant is completed in the normal way. This review normally involves a site visit of the center followed by the initial review by the CCS. The site visit and initial review will be completed without specific or detailed reference to the companion Request for Comprehensive Designation.

Following the initial review of the support grant, the CCS will conduct, in a separate session, the review of the Request. This review will address specifically the eight criteria and will be informed by: the review of the support grant application, the site visit report, the deliberations related to the review of the support grant, a two to three hour interview of the center director in which he or she represents the Request and answers specific questions of the CCS committee.

The CCS will consider all of the information in an executive session and make a recommendation for or against the comprehensiveness designation. A center must be judged acceptable in all eight of the elements for comprehensiveness in order to become an NCI-Designated Comprehensive Cancer Center.

A "Special Report on Comprehensiveness," prepared by the CCS executive secretary, will document the CCS recommendations and will be forwarded to the NCAB for final review.

**Review for interim designation:** All such Requests will be reviewed expeditiously by the NCI director following consultation with the chairman of the CCS,

### The Cancer Letter

*Editor:* Jerry D. Boyd

*Associate Editors:* Kirsten B. Goldberg  
Patricia Williams

*Editorial/Subscriptions Office:*

PO Box 15189, Washington, DC 20003

Tel: (202) 543-7665 Fax: (202) 543-6879

ISSN 096-3917. Published 48 times a year by The Cancer Letter Inc., also publisher of *The Clinical Cancer Letter* and *AIDS Update*. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form (electronic, mechanical, photocopying, facsimile, or otherwise) without prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.

the chairman of the Cancer Centers Subcommittee of the NCAB and such others as deemed necessary by the director.

This administrative designation process is available once only, and only to currently funded centers whose support grant is not timed appropriately to effect designation within the two year period through normal peer review. Existing comprehensive cancer centers must utilize this administrative process within the two year period indicated.

If the comprehensive designation is granted administratively, it will last until the next support grant renewal review, at which time the center would agree to submit a renewal Request. If the center failed to receive the designation through CCS review, it would immediately cease to use the comprehensive designation.

Should the request for administrative designation be denied, the center director may request that the CCS consider it at a regularly scheduled meeting.

**Review Criteria for Comprehensiveness:** Qualified centers with approved support grants that seek the designation of "NCI-Designated Comprehensive Cancer Center" will be evaluated in accordance with the special comprehensiveness criteria outlined below. Following review for comprehensiveness, whether by administrative or peer review procedures, the NCI director will make recommendations for comprehensive designation to the NCAB. Following competitive review of a support grant application that includes a Request for review of comprehensiveness, the NCAB would approve the comprehensive designation as part of its approval of the overall grant award.

**Basic Laboratory Research:**

--Quantity and quality of peer reviewed basic research.

--Extent of interdisciplinary interaction and collaboration among basic research programs and investigators.

--Extent to which there is evidence of interdisciplinary interactions between cancer researchers at the center (e.g., through joint publications).

**Basic/Clinical Research Linkage (Technology Transfer):**

--Extent of collaboration within the center or with appropriate outside organizations (including other research institutions or with industry) to facilitate the transfer of laboratory findings to innovative clinical use (diagnosis, treatment, prevention).

--Effectiveness of the mechanism established by the center to actively promote the transfer of technology from the laboratory to innovative clinical applications (therapeutic, diagnostic and preventive).

--Record of accomplishment in such activities.

**Clinical Research:**

--Quantity and quality of innovative clinical studies utilizing patient resources of the institution and its region.

--Extent to which such clinical studies are linked to relevant laboratories at the center.

--Record of innovative studies with new agents, or of pilot trials eventually incorporated for use in the cooperative groups or in general medical practice.

--Extent to which clinical studies at the center make special efforts to recruit from minority or underserved populations.

**High Priority Clinical Trial Research (HPCTR):**

--Record or expeditious and effective participation in HPCTR utilizing the patient resources of the region served.

--Evidence of accrual to competing trials deemed by the center to address local or regional problems with regard to specific malignancies, should a center not participate in ongoing HPCTR.

**Cancer Prevention and Control Research (CPCR):**

--Quantity and quality of peer reviewed CPCR and/or epidemiological studies and/or clinical etiology research.

--Record of effective collaboration or initiative of collaborative studies with appropriate regional organizations to conduct demonstration studies when feasible and/or regional epidemiological studies.

--Documentation of ongoing or planned participation in regional or national cancer control research.

**Education and Training:**

--Effectiveness of training programs in basic and clinical research.

--Effectiveness of programs in continuing education for local/regional health care professionals.

--Effectiveness of center's mechanism for the transfer of technology, including its record of accomplishment in training and education in state of the art procedures and instrumentation.

--Record of plans for recruiting under-represented minorities in training and education activities of the center.

**Information Services:**

--Effectiveness of programs in providing patients and their families, the public and health professionals with information about local and national resources for cancer prevention, early detection, diagnosis, treatment and rehabilitation.

--Extent to which information services are used to heighten public awareness of and participation in clinical trials, screening and other cancer control

programs of the center.

--Level of involvement with regional Cancer Information Services as applicable.

--Plans for making underserved communities (poor, minorities) aware of pertinent advances in cancer diagnosis, screening, prevention and/or treatment.

**Community Service and Outreach:** While an NCI-designated comprehensive cancer center is not required to provide prevention and control services for entire region served, reasonable efforts should be made to target outreach efforts to well defined communities and to offer technical assistance to other organizations which have a public health role.

--Clarity and appropriateness of definition of the community served by the outreach efforts of the center. (This definition may be geographic, demographic or socioeconomic. On the other hand, a center would not necessarily be expected to define a specific jurisdictional boundary such as a city limit.)

--Degree to which the center has used available resources (e.g., regional or public health agencies) in defining the characteristics and addressing special problems (e.g., cancers of high frequency) of the community served by the cancer center.

--Extent to which center is collaborating with and providing technical assistance to organizations within the defined service area which have public health, disease prevention and control and health education missions.

--Quantity and quality of proposed or ongoing efforts (including peer reviewed support) in cancer prevention and control activities, information dissemination and epidemiology directly relevant to the community served, particularly as these address incidence and mortality imbalances of cancer in populations to be served by the center.

--Considering the unique strengths of the cancer center under review and the resources available to it, are the community service and outreach efforts the most suitable use of these resources?

**Terms of Award:** Institutions that are designated comprehensive through the review process may use this designation in their title so long as review for comprehensiveness is favorable. A center failing to meet the review criteria will not be permitted to use the title, "NCI-Designated Comprehensive Cancer Center," but would still be eligible to receive funding under other centers categories, provided it met relevant criteria.

Comments and suggestions of the draft of the "Guidelines for the National Cancer Institute-Designated Comprehensive Cancer Center" may be

submitted to Barbara Bynum, Director, Div. of Extramural Activities, NCI, NIH, Bldg 31 Rm 10A03, Bethesda, MD 20892.

## **NCI Budget Could Be Cut 1.7 % Under Deficit Reduction Agreement**

Gramm-Rudman budget cuts would remain in effect through the first week in February under a plan agreed on this week by Congress and the Bush Administration.

The automatic spending reduction would result in about a 1.7 percent cut in discretionary domestic spending and 1.4 percent reduction in defense spending for total cuts of \$14.8 billion.

The cuts went into effect Oct. 1 when the government failed to reach its deficit target by the beginning of the fiscal year.

Under a continuing resolution that expired this month, NCI's budget was set temporarily at \$1.652 billion. If the agreement had not been reached, NCI's budget would have been cut by \$86.4 million, leaving a total of \$1.566 billion.

Exact figures were not available by presstime earlier this week, but if NCI's budget remains the \$1.664 as agreed upon by Congressional conferees in September, a 1.7 percent cut would result in a budget of about \$1.636, an increase over the fiscal 1989 budget of \$1.57 billion.

## **Tough Regulation Of Tobacco, Ads Proposed In \$185 Million Bill**

A bill that would bring tobacco products under federal regulatory authority and require tobacco companies to disclose the additives contained in their products was introduced last week in the Senate.

Sens. Edward Kennedy (D-MA) and Orrin Hatch (R-Utah) introduced a bill that would authorize \$185 million to establish a Center for Tobacco Products within the Centers for Disease Control. The center would assume regulatory authority over tobacco products and provide grants for education and health programs and "counter-advertising" to discourage young people from beginning to smoke.

"Tobacco use is public health enemy number one in America today," Kennedy said. "It is the leading preventable cause of death. One out of every six Americans who die this year will die from tobacco use--390,000 deaths a year, a thousand funerals a day. Smoking causes 87 percent of lung cancer and 33 percent of all cancers. It causes 40 percent of heart disease, 18 percent of strokes and 10 percent of infant

mortality. We cannot win the battle against these diseases unless we win the battle against tobacco use."

The American Medical Assn., the Coalition on Smoking OR Health and dozens of other professional and voluntary organizations immediately expressed its support for the legislation.

"The recent success of the airline smoking ban shows that Congress is willing to deal with tobacco use as the major public health problem that it is," said Raymond Scalettar, trustee of the AMA. Kennedy's bill "focuses on the segment of our population that promises the greatest potential for achieving a tobacco-free society--young people."

The legislation establishes a Center for Tobacco Products in the Centers for Disease Control. The functions of the center will be to:

--Expand federal education and information efforts on smoking and tobacco use.

--Conduct research on patterns of tobacco product use and cessation.

--Assume regulatory authority over tobacco products analogous to the authority exercised by the FDA over other products.

--Improve coordination of education and research activities of the federal government, including activities of the NIH and the Dept. of Education.

--Emphasize education and prevention programs for high risk individuals, such as pregnant women, and those with the highest prevalence of tobacco use, such as school dropouts, minorities and blue collar workers.

--The bill seeks \$50 million to be authorized for the center's administration in FY 1991.

The center would administer a series of other programs and grants:

--A national counter-advertising program. Grants will be provided to develop public service announcements and ads to discourage tobacco use. The bill seeks \$50 million for these grants. Kennedy noted that the \$50 million represents only 2 percent of the tobacco industry's \$2.5 billion advertising and promotion budget.

--Incentive grants to states to encourage enactment and better enforcement of laws which prohibit the sale of tobacco products to minors. Another \$50 million is sought for this program.

--"Leadership" grants to 10 to 20 states to strengthen state departments of health and develop better structures to prevent initial use of tobacco and encourage cessation. The bill seeks \$5 million for this program.

--"Workplace intervention" grants to public and private organizations to help reduce tobacco use in the workplace and to educate workers about the

dangers of smoking. Emphasis would be given to cooperative projects involving labor organizations and employers. The bill would allocate \$5 million for this program.

The center would be authorized to enter into cooperative agreements with up to 10 states to assist in their efforts to implement existing laws prohibiting the sale of tobacco products to minors.

The bill also requires full disclosure of additives to each brand of tobacco and authorizes hazardous additives to be restricted.

"It is time to end the disgraceful abdication of federal responsibility that makes tobacco the only consumer product today that has serious consequences for public health but that is essentially uncontrolled," Kennedy said. "Additives to food are strictly regulated by the FDA, and it is time to stop permitting the industry to treat additives to tobacco as trade secrets."

The current warning label ("Surgeon General's Warning: Cigarette smoke contains carbon monoxide.") would be replaced with a new label: "Surgeon General's Warning: Smoking is addictive. Once you start you may not be able to stop." The bill also would repeal the current federal preemption with respect to regulation of local tobacco advertising and promotion.

The bill adds tobacco to the curriculum program required in the Drug Free Schools and Communities Act of 1986. It provides for a separate program of innovation grants to states to encourage elementary and secondary schools to become smoke free. The bill would provide \$25 million for this program.

## **ONS Announces 1990 Nursing Exam; 79 Percent Passed Test Last Year**

The Oncology Nursing Society announced that the 1990 Oncology Nursing Certification Examination will be offered May 16 in conjunction with the ONS 15th Annual Congress, to be held in Washington.

The examination also will be given on Sept. 22 in New York City, Atlanta, Chicago, Dallas, Denver and Los Angeles. If there is no test center within 100 miles of an applicant's location, an additional test center may be established by contacting the Oncology Nursing Certification Corp. Nurses eligible for renewal may take the test on either date.

Last September, 1,614 registered nurses, or 79 percent of the 2,042 who sat for the examination, passed, bringing the total number of oncology certified nurses to 7,236. Certification was introduced at the 1986 ONS Congress in Los Angeles, where 1,384 nurses passed the first exam.

The examination is aimed at testing the general oncology nursing knowledge base of the professional nurse.

The names of OCNs will become public information and a list of successful candidates will be published by the ONCC.

Certification is open to nurses who have: current RN license, two and a half years experience as an RN within the last five years, and a minimum of 1,000 hours of oncology nursing practice within the last two and one half years.

The cost of the exam is \$175 for ONS members, \$250 non members. Renewal fees are \$125 ONS members, \$200 non members. Certification is effective for four years.

For more information contact Oncology Nursing Certification Corp., 1016 Greentree Rd, Pittsburgh, PA 15220-3125, phone 412/921-8597.

Travel grants are available to ONS members who will be presenting or moderating a session at the 15th International UICC Congress, to be held Aug. 16-22 in Hamburg, West Germany. The travel grants, provided by the American Cancer Society, will cover part of the congress expenses.

An ONS review committee will select 25 recipients to receive \$1,200 each to help defray expenses. Recipients will be asked to submit a report on their participation in the congress and ONS will submit a final report to ACS. Applicants for the awards may be obtained by calling ONS at 412/921-7373. The application deadline is March 1.

Oncology Nursing Foundation has launched a national fundraising campaign with publication of "The Caring Cook," a collection of recipes submitted by ONS members. Proceeds will be used to improve the quality of nursing care. Copies are available by sending \$14.95 plus \$1.50 postage to Oncology Nursing Foundation, 1016 Greentree Rd., Pittsburgh, PA 15220, or phone 412/921-7373.

## NCI Advisory Group, Other Cancer Meetings For Dec., Jan., Future

**Current Aspects of Treatment of Soft Tissue Sarcoma**--Dec. 1, Buffalo, NY. Contact Gayle Bersani, Roswell Park Memorial Institute, Carlton & Elm Sts., Buffalo, NY 14263, phone 716/845-2339.

**BASO Winter Meeting**--Dec. 1-2, London, UK. General oncological subjects. Contact British Assn. of Surgical Oncology, Lincoln's Inn Fields, London WC2A 3PN, UK.

**Breast Cancer: New Developments in Biology, Diagnosis & Treatment**--Dec. 3-9, London, UK. Contact The British Council, 65 Davis St., London W1Y 2AA, UK.

**National Cancer Advisory Board**--Dec. 4-5, NIH Bldg 31, Rm 10, 8:30 a.m. Dec. 4, 8 a.m. Dec. 5. Open except Dec. 5 from 1:45

p.m. (approximately) to 2:15 p.m.

**NCAB Committee on Information & Cancer Control**--Dec. 4, NIH Bldg 31 Rm 7, 7:30 a.m., open.

**NCAB Committee on Planning & Budget**--Dec. 4, NIH Bldg 31 Rm 8, to start immediately after end of full NCAB session, probably 5 p.m., open.

**NCAB Committee on Special Actions**--Dec. 5, NIH Bldg 31 Rm 10, approximately 1:45 p.m.-2:15 p.m., closed. Open session of full board to resume at approximately 2:15.

**Hamburger Symposium uber Tumormarker: Recent Results in Tumor Diagnosis & Therapy**--Dec. 4-6, Hamburg, W. Germany. Contact Dr. R. Klapdor, I. Dept. of Medicine, Univ. Hospital, Martinstrasse 52,2, Hamburg 20, FRG.

**Foundation Course in Care of the Patient With Advanced Cancer**--Dec. 4-8, Oxford, UK. Contact Study Centre Coordinator, Sir Michael Sobell House, The Churchill Hospital, Oxford, OX37LJ, UK.

**National Committee to Review Current Procedures for Approval of New Drugs for Cancer & AIDS (Lasagna Committee)**--Dec. 7, NIH Bldg 31, Rm 10. Location may be changed, contact Dr. Elliott Stonehill, 301/496-1148.

**12th Annual San Antonio Breast Cancer Symposium**--Dec. 8-9, San Antonio, TX. Sponsored by Cancer Therapy & Research Foundation of South Texas and the American Cancer Society. Contact Lois Dunnington, 512/567-4745.

**President's Cancer Panel**--Dec. 11, Bethesda. Bldg 31C Rm 6. Contact Winifred Lumsden, 301/496-5708.

**Leukemia & Lymphomas**--Dec. 11-12, London, UK. Contact B. Cavilla, Institute of Biology, 20 Queensberry Place, London, SW7 2DZ, UK.

**Developmental Therapeutics Program**--Dec. 14-15, Bethesda. Bldg 31C Rm 9. Open 9-10 a.m. on Dec. 14. Contact Winifred Lumsden, 301/496-5708.

**Current Therapies in Veterinary Oncology**--Dec. 16, Portofino, Italy. Contact Servizio Attivita Culturali, Istituto Nazionale per la Ricerca sul Cancro, V. le Benedetto XV, 10, 16132 Genova, Italy.

**Sixth National Cancer Communications Conference**--Jan. 10-12, Washington. Sponsored by NCI and American Cancer Society. Contact Communications Conference, 1801 Rockville Pike, Suite 500, Rockville, MD 20852, phone 301/468-6338.

**11th Congress, Assoc. of Radiation Oncologists of India**--Jan. 11-14, Nagpur, India. Contact Dr. Harish Kulkarni, Cancer Centre, Manewada Rd, Nagpur 440 003, India.

**Ionizing Radiation Damage to DNA: Molecular Aspects**--Jan. 16-21, Lake Tahoe, CA. Sponsored by Radiation Research Society. Contact UCLA Symposia, 2032 Armacost Ave, Los Angeles, CA 90025.

**Cancer Biotherapy Symposium**--Jan. 17-18, Orlando, FL. Sponsored by Orlando Regional Medical Center, Biological Therapy Institute, and National Biotherapy Study Group. NBSG semiannual meeting immediately follows symposium. Contact Patti Devlin, Orlando Regional Medical Center, 1414 Kuhl Ave., Orlando, FL 32806, phone 1-800-648-0450.

**6th Annual Cancer Symposium**--Jan. 18, Mosul, Iraq. Contact Dr. Ayad H. Al-Ramadhani, Iraqi Cancer Society, Mosul Branch, PO Box 760, Mosul, Iraq.

**Molecular Basis of Cellular Adhesion**--Jan. 20-26, Steamboat Springs, CO. Sponsored by Benentech and Glaxo. Contact UCLA Symposia, 2032 Armacost Ave., Los Angeles, CA 90025.

**Teaching Course on Brachytherapy**--Jan. 22-26, Villejuif, France. Contact ESTRO Secretariat, Dept. Radiotherapy, VH St. Rafael Capucijnenvoer 35, 3000 Leuven, Belgium.

**American Cancer Society National Conference on Advances in Cancer Imaging**--Jan. 24-26, New York. Contact ACS, 1599

Clifton Rd NE, Atlanta, GA 30329, phone 404/329-7604.

#### FUTURE MEETINGS

**24th Annual Clinical Symposium**--Feb. 23, Memphis, TN. Contact Director, St. Jude Children's Research Hospital, Box 318, Memphis, TN 38101, phone 901/522-0300.

**Combining Biological Response Modifiers with Cytotoxics in the Treatment of Cancer**--March 5-7, Baltimore, MD. Sponsored by NCI Div. of Cancer Treatment. Contact Debra Casey or Abbe Smith, Technical Resources Inc., 301/770-3153, fax 301/231-6377.

**American Society of Preventive Oncology Annual Meeting**--March 19-21, Bethesda, MD. Contact Dr. Richard Love, ASPO, 1300 University Ave. 7C, Madison, WI 53706, phone 608/263-6919.

**International Conference on Health Effects of Omega-3 Polyunsaturated Fatty Acids in Seafoods**--March 20-23, Washington. Contact Dr. Roy Martin, National Fisheries Institute, 2000 M St. NW Suite 580, Washington, D.C. 20036, phone 202/296-5172.

**22nd Annual Cancer Symposium: Anticancer Drug Discovery and Development**--April 26-28, Detroit. Sponsored by Metropolitan Detroit Cancer Center, Wayne State Univ. and Harper Hospital. Contact Dr. Frederick Valeriote, Deputy Director, Div. of Hematology and Oncology, Dept. of Medicine, Wayne State Univ., PO Box 02188, Detroit, MI 48202, phone 313/745-8252.

**Ambulatory Care Nursing Conference**--April 26-27, San Diego, CA. Sponsored by Kaiser Permanente, Sharp Res-Stealy Medical Centers, Scripps Clinic and Research Foundation and Univ. of California (San Diego). Contact Shirley Kolkey, Meeting Management, 5665 Oberlin Dr. Suite 110, San Diego, CA 92121, phone 619/453-6222.

**National Conference on Cancer and the Changing Healthcare System**--May 3-5, San Francisco, CA. Sponsored by American Cancer Society. Contact ACS, 1599 Clifton Rd. NE, Atlanta, GA 30329, phone 404/329-7604.

**Oncology Nursing Society**--May 16-19, Washington, D.C. Contact ONS, 1016 Greentree Rd, Pittsburgh, PA 15220-3125, phone 412/921-7373.

**Complications of Treatment of Children and Adolescents for Cancer**--June 22-24, Buffalo, NY. Contact Daniel Green, Dept. of Pediatrics, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY 14263, phone 716/845-2333.

## New Publications

"Congressional Directory: Environment," edited by Betty Farley and John Grupenhoff. Hardbound, 600 page directory of members of Congress, environment legislative aides for all 535 members; key staff on the 79 committees and subcommittees dealing with the environment; environment interests of many members in comprehensive biographies; key word indexes listing nearly 500 environment issues, referenced to committee and subcommittee jurisdictions. Published by Environment Communications, a subsidiary of Grupenhoff's Science and Health Communications Group, which represents various health related constituencies, including the American Society of Clinical Oncology and the Assn. of American Cancer Institutes. Environment Communications, 6410 Rockledge Dr., Suite 203, Bethesda, MD 20817, phone 301/571-9791, \$87.50 prepaid, add \$4.50 for postage

and handling if billed. Price includes 320 page paperback "Blueprint for the Environment," plus 90 day update lists of members and environment aides.

"Tumor Registry Desk Reference: Volume 1, Directory of Oncology Related Organizations and Publications--1989," edited by April Fritz. Details 90 organizations interested in cancer, 130 standard reference books, and 120 cancer journals and periodicals. Available from National Tumor Registrars Assn., 505 E. Hawley St., Mundelein, IL 60060, \$25.

"Extremely Low Frequency Electromagnetic Fields: The Question of Cancer," edited by Bary Wilson, Richard Stevens, and Larry Anderson of Battelle Pacific Northwest Laboratories. Battelle Press, 505 King Ave., Columbus, OH 43201, \$57.50.

"Periodic Screening for Breast Cancer," edited by Sam Shapiro, Wanda Venet, Philip Strax, and Louis Venet. The Health Insurance Plan Project and its Sequelae, 1963-1986. Comprehensive history of the landmark HIP study, including new findings that confirm the HIP results and examine policies adopted in several countries to promote breast cancer screening. Johns Hopkins Univ. Press, 701 W. 40th St., Suite 275, Baltimore, MD 21211, \$35.

"Breast Cancer Treatment Options: Choosing What is Right for You," produced by Terry Greem. Thirty seven minute videotape to help newly diagnosed patients sort out treatment options. Developed in consultation with multidisciplinary panel of oncologists. Health Care Communications, St. Joseph Office Park, 1401 Harrodsburgh Rd., B160, Lexington, KY 40504, \$79.95 (discounts for multiple copies).

"Medical, Biochemical, and Chemical Aspects of Free Radicals," edited by O. Hayaishi, E. Niki, M. Kondo, and Y. Yoshikawa. Proceedings of the 4th Biennial Meeting of the Society for Free Radical Research in Kyoto, Japan, 1988. Elsevier Science Publishers, PO Box 882, Madison Square Station, New York 10159, or PO Box 211, 1000 AE Amsterdam, The Netherlands, \$513.25 U.S. or Dfl. 975, two volumes.

"Hodgkin's Disease: The Consequences of Survival," by Mortimer Lacher and John Redman. Reexamination of treatment modalities in light of long term consequences that befall seemingly cured Hodgkin's patients. Lea & Febiger, 600 S. Washington Square, Philadelphia, PA 19106, \$80.

The following are available from Kluwer Academic Publishers, 101 Philip Dr., Norwell, MA 02061:

"Cancer Growth and Progression," edited by Hans Kaiser. Ten volume set, \$895. Brochure available describing each volume which may be purchased separately for \$99.50.

"Transition Metal Complexes as Drugs and Chemotherapeutic Agents," by Nicholas Farrell, \$89.

"Annals of Oncology," official journal of the European Society for Medical Oncology, F. Cavalli, editor in chief. Annual subscription (six issues), \$134, special rate for ASCO members, \$86.50.

"International Handbook of Pancreas Transplantation," edited by J.M. Dubernard and D.E.R. Sutherland. Review of work in the past decade. \$185.

"Pancreas Transplantation," edited by Luis Toledo-Pereyra. \$135.

"Biopathology of the Liver: An Ultrastructural Approach," edited by P.M. Motta. \$122.

"Liver Cell Carcinoma," edited by P. Bannasch, D. Keppler and G. Weber. Proceedings of the Falk Symposium held in Freiburg, W. Germany in 1988. \$121.50

"Endosonography," edited by Bruno Fornage. \$129.

"Intraoperative Ultrasonography in Hepato-Biliary and Pancreatic Surgery: A Practical Guide," edited by G. Gozzetti, A. Mazziotti, L. Bolondi and L. Barbara. \$92.50.

"Clinical Research in Gastroenterology 2," edited by S. Matern. \$35.

"Modulation of Liver Cell Expression," by Reutter. \$102.

"X-Ray Differential Diagnosis in Small Bowel Disease," by Sellink. \$99.50.

"Nerves and the Gastrointestinal Tract," edited by M.V. Singer and H. Goebell. \$165.

"Bile Acids in Health and Disease," edited by T.C. Northfield, P. Zentler-Munro and R. Jazwari. \$74.

"Trends in Bile Acid Research," edited by G. Paumgartner, A. Stiehl and W. Gerok. \$89.

The following are available from Raven Press, 1185 Avenue of the Americas, New York 10036:

"Antiviral Agents and Viral Diseases of Man," edited by George Galasso, Richard Whitely, and Thomas Merigan. Third edition, \$145.

"Radiology of AIDS," edited by Michael Federle, Alec Megilbow, and David Naidich, \$89.

"Principles of Cancer Biotherapy," edited by Robert Oldham, \$89.

"Regulation of Cell Growth and Activation," edited by James Mond, John Cambier, and Arthur Weiss, \$78.

"Enhancing the Role of Cancer Nursing," edited by Carol Ash and Jean Jenkins, \$46.

"Bone Marrow Transplantation in Children," edited by Leonard Johnson and Carl Pochedly, \$110.

"Interpretation of Breast Biopsies (second edition)," edited by Darryl Carter, \$65.

"Pediatric Radiation Oncology," edited by Edward Halperin, Larry Kun, Louis Constine, and Nancy Tarbell, \$98.

## RFPs Available

Requests for proposals described here pertain to contracts planned for award by the National Cancer Institute unless otherwise noted. NCI listings will show the phone number of the Contracting Officer or Contract Specialist who will respond to questions. Address requests for NCI RFPs, citing the RFP number, to the individual named, the Executive Plaza South room number shown, National Cancer Institute, Bethesda MD 20892. Proposals may be hand delivered to the Executive Plaza South Building, 6130 Executive Blvd., Rockville MD. RFP announcements from other agencies will include the complete mailing address at the end of each.

### RFP NCI-CN-95165-38

Title: ASSIST Cancer Prevention

Deadline: Approximately Sept. 25, 1990

The goal of this acquisition is to apply a specific set of proven state of the art smoking prevention and control interventions developed in randomized research trials throughout approximately 20 demonstration sites. These sites will form the framework through which to implement and institutionalize these intervention strategies in order to reduce smoking prevalence.

This framework will comprise a coalition of community and state level organizations and agencies which have the capacity and/or the mandate to reach smokers and youth at risk of becoming smokers. The proposed RFP will restrict competition to health departments in states or large metropolitan areas which have the capability to meet the government requirements in cooperation with a voluntary health agency. The statutory authorities used to justify the limited field of competition are 41 USC 253 (c)(3) and FAR 6.302-3. The latter states: "Full and open competition need not be provided for when it is necessary to award the contract to a particular source or sources in order...to establish or maintain an essential engineering, research or development capability to be provided by an educational or other nonprofit institution." The FAR goes on to cite appropriate use of this exception when it is necessary to "Establish or maintain an essential capability for...developmental work calling for the practical application of investigative findings and theories of a scientific or technical nature." Twenty awards are anticipated for 6.5 year incrementally funded cost reimbursement contracts.

Contracting Officer: Barbara Mercer

RCB Executive Plaza South Rm 635

301/496-8603

### RFP NCI-CM-07314-19

Title: Logistics and conference support

This RFP has been cancelled.

Contracting Officer: J. Thomas Lewin

RCB Executive Plaza South Rm 603

301/496-8620

## NCI Contract Awards

Title: Support of biochemical and epidemiology studies

Contractor: Microbiological Associates Inc., Rockville, MD; \$5,755,352

Title: Partial support of institute of laboratory animal resources

Contractor: National Academy of Sciences; \$237,500



